Early Infliximab Trough Levels Predict Remission at One Year in Pediatric IBD Patients

Rosenthal, Casey J.; Melmed, Gil Y.; Tripuraneni, Bhavna; Gebbia, Jennifer; Callejas, Silvia; Farrior, Sharmayne; Rabizadeh, Shervin; Dubinsky, Marla C.

doi:10.1097/00054725-201212001-00197

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, ADAbs can also take months to reach detectable levels (Table 3). 26,37,38,41,47,[49][50][51][52][53][54][55][56][57][58][59][60][61] Pharmacoeconomics We identified only one study that addressed pharmacoeconomic issues related to the development of immunogenicity to biologic therapy in IBD; this Danish study involved 69 patients with CD with secondary IFX failure receiving either IFX dose intensification (5 mg/kg every 4 weeks) or interventions based on serum IFX and IFX antibody levels. 62 The authors concluded that monitoring of ADAbs to IFX in patients with CD was more costeffective than dose escalation without drug monitoring and immunogenicity assessment.…”

Section: Impact Of Adab Formation On Treatment Pharmacokineticsmentioning

confidence: 99%

Immunogenicity of biologics in inflammatory bowel disease

Vermeire

Gils

Accossato

et al. 2018

Therap Adv Gastroenterol

181

146

View full text Add to dashboard Cite

Crohn’s disease and ulcerative colitis are chronic inflammatory disorders of the gastrointestinal tract. Treatment options include biologic therapies; however, a proportion of patients lose response to biologics, partly due to the formation of anti-drug antibodies (ADAbs). Concomitant immunosuppressive agents reduce the development of ADAbs. This review article aims to assess the immunogenicity of biologic therapies and their clinical implications. A comprehensive literature search was conducted for articles published January 2009 to August 2015 reporting immunogenicity to adalimumab (ADM), certolizumab pegol (CZP), golimumab, infliximab (IFX), ustekinumab, and vedolizumab in inflammatory bowel disease (IBD). Eligible articles were reviewed and quality assessed by independent reviewers. Overall, 122 publications reporting 114 studies were assessed. ADAbs were reported for all agents, but the percentage of patients developing ADAbs was extremely variable, with the highest (65.3%) being for IFX administration to patients with IBD. ADAb presence was frequently associated with a reduction in primary efficacy and a loss of response, and, for IFX, an increase in adverse events (AEs). Lower serum levels of ADM, CZP and IFX were seen in ADAbs-positive rather than ADAbs-negative patients; pharmacokinetic data were unavailable for other therapies. Little information was available regarding the timing of ADAb development; studies reported their detection from as early as 10–14 days up to months after treatment initiation. Biologic therapies carry an intrinsic risk of immunogenicity, although reported rates of ADAbs vary considerably. The clinical implications of immunogenicity are a concern for effective treatment; further research, particularly into the more recently approved biologics, is required.

show abstract